Flagship · Bulletin

Macro rationale

Unchanged from the 10-05 audit. The extension escalator is still active (QQQ +12.49% vs its 200d, weekly RSI 65.7), which lifts the cash ceiling to 30%. The high-yield stress trigger no longer fires and credit spreads stay calm. VIX is 15.08 in contango (VIX/VIX3M 0.85), so the market is not stressed. The pressure is rates and oil. The 10y is 5.27%, up 47bp in 20 days, which is through the paper's 5.25% 'deepen defensiveness' line. Real yields are 2.91% (+48bp in a month). The dollar is up 2.4% over the month. Hormuz is effectively closed and attacks are spreading to Qatar and Fujairah, with WTI at $96. Breadth is narrow: 25% of sectors sit above their 50d and equal-weight trails SPY by 3.8pp. Biology is the weakest pillar at -9.6pp versus SPY over the month, as you'd expect from a long-duration sector facing a 5%+ 10y. None of this is a credit or capex break, so NEUTRAL holds. Cash stays at the 20.8% entry level: no escalator fired or cleared, no named open is being funded and no exit is being banked, so there is no cause to move it.

Thesis

This was an event-driven wake on ARGX: -14.1% on 3.1x average volume. It gapped from $928 to ~$831 at the open and is trading ~$796, roughly -25% from its early-September ~$1,055. I pulled the thread: the ARGX news feed through Oct 7 is uniformly constructive (Halozyme ENHANZE expanded from six to eight targets, AANEM/MGFA durability data, Forte closed), and Immunovant's feed carries no fresh FcRn readout. So the gap has no NAMED cause in the evidence. The fresh briefer verdict is intact, the funders (Fidelity, T. Rowe) have not reversed, and no unwind condition is verifiably triggered. A biotech gap of this size often means clinical or pricing news. If it turns out to be a myositis/Sjogren's miss or a pricing action, that hits a named unwind condition and the IC re-underwrites size then. On price alone it is a hold, not an add, and not a trim. Buying an unexplained gap is not conviction, and selling one is not discipline. LLY (-3.9% today, sector tape, Jaypirca approval just landed), VRTX and BEAM are re-underwritten intact. Book-wide, nothing changed since the 10-05 audit. The AVGO 'NEAM exit' flag concerns a small non-core holder against Norges' $24.9B new stake, so it is not a funder break. Result: 17 verbatim holds, zero tickets, and cash stays at the 20.8% entry level inside the escalated neutral band.

Reflection

No funder broke. ARGX's -14% gap has no named cause in the feed; sovereigns are still adding to compute and power, and biology is the weakest pillar under a 5.27% 10y.

ARGX is now ~25% off its September high in a steady slide that ended in a gap. The news feed shows only positives, which makes me suspicious that the cause (a trial readout, competitor data or a pricing headline) simply has not reached the feed yet. Holding is the right call on missing information, but I am noting that I have no named reason for the move. LLY fell 3.9% the same day, so a sector-wide pricing headline is possible; that would hit the pricing unwind condition on both. The biology pillar is -9.6pp vs SPY over the month, consistent with the paper's rate-headwind read. The next IC sh

Positions

• KTOSKratos Defensedefense

  hold6.00%56
  flow softeningconf

  Funder

  Scarce non-prime supplier of attritable airframes (XQ-58A Valkyrie), hypersonic test vehicles and small turbines, with program positions embedded for a decade; rev +32% YoY, FY guide raised. Wind: MACH-TB 2.0 $1.45B IDIQ, >$100M of new space/cyber awards, Prometheus solid-rocket-motor JV with RAFAEL, and the FY27 $1.5T request's ~$103B autonomy line. Already right-sized to 6% on 10-05 for cash bur

  Unwind

  Backlog or contract cancellations; FCF still negative through FY2027 with no margin inflection; another discounted equity raise; a full-year FY27 CR freezing production ramps; further misses on the tactical-drone leg after Gauntlet 2.

  Catalyst

  Q3 print ~Nov 3: margin firming and FCF trajectory; Dec 11 CR expiry / FY27 appropriations.

  Scenarios · 12mo targets

  $52.00 base

  $75.00 bull — Valkyrie/CCA production orders land, MACH-TB task orders scale, OM inflects toward 5% and FCF turns positive.

  $28.00 bear — A year-long CR freezes ramps, the drone leg loses more competitions, and a fresh raise dilutes again.

• HEIHEICOdefense

  hold10.23%64
  flow steadyconf

  Funder

  Run by the Mendelson family since 1957. FAA-PMA replacement parts plus niche defense electronics, compounding FCF >20%/yr through cash-funded tuck-ins. 40.3% GM, 24.1% OM, 16.5% FCF margin, 13.7% ROIC, 1.6x ND/EBITDA, share count flat, rev +36.5%. Wind: ARK +50k sh in Q2, airline utilization still rising, Zacks Strong Buy on rising estimates.

  Unwind

  Organic growth <6% with margin compression; a large value-destroying acquisition that breaks tuck-in discipline; a Mendelson succession that removes the capital-allocation edge; FAA/OEM action against PMA parts.

  Catalyst

  FQ4 print ~late Nov; airline aftermarket commentary at Q3 airline earnings.

  Scenarios · 12mo targets

  $340.00 base

  $390.00 bull — PMA share gains accelerate as airlines fight OEM part inflation, and defense electronics ride the munitions build.

  $240.00 bear — An air-travel downturn cuts aftermarket demand while the multiple de-rates toward the industrial average.

• SCCOSouthern Copperenergy

  hold8.30%65
  flow steadyconf

  Funder

  §5.3 tail-risk hedge: the lowest-cost major copper producer with the industry's largest reserve base. 67.6% GM, FCF positive, large dividend; Grupo Mexico control keeps capital discipline through the cycle. Wind: structural copper deficit, the $10.2B Mexican expansion (El Pilar, 2029), H1 operating cash +117% YoY, and grid/AI copper demand.

  Unwind

  A copper price collapse that breaks the deficit thesis; Tia Maria/Los Chancas permitting reversed; a dividend cut signalling stress; nationalist royalty shocks in Peru or Mexico.

  Catalyst

  Q3 print late Oct; copper inventory/LME spreads; Tia Maria commissioning updates.

  Scenarios · 12mo targets

  $210.00 base

  $260.00 bull — Supply disruptions tighten copper further and Tia Maria ramps on schedule.

  $140.00 bear — Chinese demand rolls over and copper reverts as the Hormuz premium fades.

• TSMTaiwan Semiconductor Manufacturingcompute

  hold7.75%83
  flow steadyconf

  Funder

  Anchor. In effect the only foundry at ≤3nm: essentially every AI accelerator routes through it. CoWoS booked 52-78 weeks out, ~10% price premium absorbed by customers, A14 tape-outs. Wind: ARK +482k sh in Q2, big-four hyperscaler capex ~$725B in 2026 heading toward ~$1T in 2027, Arizona build-out under CHIPS.

  Unwind

  GM <50% for two consecutive quarters; a rival closing the leading-edge yield gap; a Taiwan Strait event Arizona capacity cannot offset; a NAMED hyperscaler capex cut.

  Catalyst

  Q3 earnings Oct 15 (EPS +52% YoY expected), 2027 capex guide.

  Scenarios · 12mo targets

  $540.00 base

  $620.00 bull — 2027 capex guide raised, N2 ramp clean, and CoWoS pricing extends margins above 60%.

  $340.00 bear — An AI capex digestion pause plus a Strait scare compress the multiple to its historical median.

• LLYEli Lillybiology

  hold6.66%75
  flow steadyconf

  Funder

  Anchor. Premier pharma compounder: 84.1% GM, 38.8% OM, 26.4% ROIC, rev +67.9%, share count -1.2%, plus a $27B manufacturing moat. Tirzepatide, oral orforglipron (approved Apr 2026) and retatrutide in Ph3. Wind: Oct 6 Jaypirca first-line CLL/SLL approval (80% risk reduction), still leading GLP-1 share. Today's -3.9% move is sector tape with no named break.

  Unwind

  Tirzepatide US script share falling >5pts to Novo or an oral entrant over two quarters; a retatrutide Ph3 safety or durability miss; IRA/MFP negotiation or a most-favored-nation pricing action that resets GLP-1 net price.

  Catalyst

  Q3 print ~Oct 29-Nov 4; orforglipron launch scripts; retatrutide TRIUMPH readouts.

  Scenarios · 12mo targets

  $1,300.00 base

  $1,550.00 bull — Orforglipron uptake broadens the market, retatrutide data sets a new efficacy bar, and Jaypirca adds an oncology leg.

  $880.00 bear — An MFN-style pricing action cuts GLP-1 net price while oral competitors take share.

• VRTXVertex Pharmaceuticalsbiology

  hold6.02%80
  flow steadyconf

  Funder

  Anchor. The CF monopoly (Trikafta/Alyftrek) is a self-funding cash engine: 86.2% GM, 38.2% OM, 21.3% FCF margin, 26.7% ROIC, net cash, share count -1.7%, patents into the late 2030s. The non-CF leg is confirming: inaxaplin Ph2b cut UACR 42.7% in AMKD (9/23), suzetrigine is launching, and Casgevy is ramping.

  Unwind

  The CF franchise eroding faster than non-CF revenue replaces it; the Crinetics integration destroying value; suzetrigine commercial failure; an inaxaplin pivotal miss that removes the renal leg.

  Catalyst

  Q3 print ~Nov 3: suzetrigine scripts and the Casgevy patient-initiation count.

  Scenarios · 12mo targets

  $570.00 base

  $660.00 bull — Suzetrigine scales in acute pain and inaxaplin's pivotal data confirms a second multi-billion franchise.

  $410.00 bear — A slow suzetrigine launch leaves the business valued as a single-product CF annuity.

• NEMNewmontenergy

  hold5.47%85
  flow steadyconf

  Funder

  §5.3 tail-risk hedge and anchor: largest gold producer, tier-1 long-life assets. 54.4% OM, 36.3% FCF margin, 28.5% ROIC, net cash, share count -5.3% YoY. Record Q2 FCF of $2.2B funds dividends and buybacks. Wind: central-bank gold buying, the Hormuz conflict premium, and Puna expansion.

  Unwind

  Cost overruns breaking FCF or the dividend (AISC toward ~$1,680/oz with the 13% production decline is the live version); a gold rollover on genuine disinflation plus a hawkish real-yield spike.

  Catalyst

  Q3 print ~Oct 22: AISC and production guidance.

  Scenarios · 12mo targets

  $130.00 base

  $160.00 bull — Gold holds a war premium and AISC stabilizes, so FCF funds outsized buybacks.

  $85.00 bear — Hormuz reopens, real yields keep climbing, gold corrects and costs overrun.

• GEVGE Vernovaenergy

  hold3.71%63
  flow acceleratingconf

  Funder

  Gas-turbine and grid franchise with pricing power: heavy-duty turbines sold out through 2030, 10-20% price realization, backlog pulled forward toward ~$200B by early 2027, 32.7% ROIC, 39.8% FCF margin, net cash. Wind: Norges NEW +3.42M sh, Temasek +372%, Coatue/Tiger/KIC/Fidelity all adding in Q2; first US construction permit for BWRX-300; Google nuclear upgrade funding.

  Unwind

  Gas-turbine backlog cancellations or a NAMED hyperscaler power-capex cut; wind losses widening enough to consume gas-segment profit; order intake falling below sales.

  Catalyst

  Q3 print ~Oct 21: orders, backlog and margin guide.

  Scenarios · 12mo targets

  $1,150.00 base

  $1,350.00 bull — Q3 orders lift the backlog past $200B early and SMR orders follow the TVA permit.

  $750.00 bear — Hyperscaler power procurement pauses and wind charges hit margins.

• ARGXargenxbiology

  hold3.79%69
  flow softeningconf

  Funder

  Vyvgart/Vyvgart Hytrulo FcRn autoimmune franchise: first-mover, commercial-stage, ~60% YoY revenue growth, net cash, self-funding a decade of label expansion (all gMG serotypes, CIDP, myositis, Sjogren's). Wind: Fidelity +5.23M and T. Rowe +2.68M sh in Q2; Oct 7 Halozyme ENHANZE expansion from six to eight targets; Forte/FB102 deal closed. The -14% gap has no named cause in the news feed, so this

  Unwind

  Vyvgart revenue growth stalling; a myositis or Sjogren's Ph3 failure; J&J nipocalimab or UCB rozanolixizumab taking material share; a dilutive raise; a pricing action. If today's cause proves to be one of these, re-underwrite size at the IC.

  Catalyst

  Identification of the Oct 8 gap cause; Q3 product sales late Oct; myositis/Sjogren's Ph3 readouts.

  Scenarios · 12mo targets

  $950.00 base

  $1,200.00 bull — The gap proves non-fundamental, Q3 Vyvgart sales beat, and the myositis/Sjogren's labels extend the runway.

  $600.00 bear — The gap is a pivotal-indication failure or a pricing hit, growth decelerates and next-gen FcRn rivals compress the multiple.

• MUMicron Technologycompute

  hold3.91%75
  flow steadyconf

  Funder

  Anchor. The only US-domiciled leading-edge DRAM/HBM franchise: 72.5% GM, 65.4% OM, 60.8% ROIC, net cash, record quarterly revenue, a three-player HBM oligopoly under Strategic Customer Agreements. Wind: Norges NEW $17.5B plus a 4-fund cluster open, Coatue +1794%, KIC/Temasek/Mubadala adding; CEOs across the chain flagging memory shortages; CHIPS-funded Idaho/NY fabs.

  Unwind

  Erosion of the Strategic Customer Agreement book or customer deposits returned; HBM oversupply as 2027 Samsung/SK capacity lands; CXMT converting DRAM share at the leading edge.

  Catalyst

  FQ1 print ~late Dec; HBM4 qualification at the major accelerator customers.

  Scenarios · 12mo targets

  $1,150.00 base

  $1,450.00 bull — Shortage pricing persists into 2027 and HBM4 share holds above 20%.

  $650.00 bear — 2027 capacity floods DRAM, contract prices roll over and the cycle multiple compresses.

• NVDANVIDIAcompute

  hold3.54%69
  flow acceleratingconf

  Funder

  AI-accelerator franchise with the CUDA moat: 74.2% GM, 74.1% ROIC, net cash, rev +138% YoY, $235B buyback authorization, share count -1.3%. Wind: Norges NEW $65.2B, Temasek +3554%, KIC/Tiger/Coatue adding in Q2; hyperscaler capex heading toward ~$1T in 2027.

  Unwind

  Data-center revenue growth <20% YoY for two consecutive quarters; GM below the 71-72% floor on memory cost; the receivables build (45→60 DSO) persisting while cash conversion weakens.

  Catalyst

  FQ3 print ~Nov 25; Rubin ramp commentary.

  Scenarios · 12mo targets

  $275.00 base

  $330.00 bull — Rubin ramps on time and sovereign/enterprise AI broadens demand past the hyperscalers.

  $165.00 bear — Capex digestion plus ASIC substitution cuts growth, and memory costs squeeze GM.

• ASMLASML Holdingcompute

  hold2.60%68
  flow steadyconf

  Funder

  EUV/High-NA monopoly, the irreplaceable tool at 2nm: multi-year backlog, ~50% GM, an installed-base service annuity (+31.8% YoY). Wind: weekly buybacks executing (€428M Sep 14-18), TSMC/Intel/Samsung leading-edge capex, Terafab and other new-fab announcements.

  Unwind

  Book-to-bill <0.7 for three consecutive quarters; Dutch/US export tightening removing a material share of the orderbook (China 20-33% of revenue); High-NA adoption slipping past 2028.

  Catalyst

  Q3 orders print mid-Oct; 2027 guide.

  Scenarios · 12mo targets

  $2,050.00 base

  $2,400.00 bull — Q3 bookings surge on 2nm and memory EUV layers, and High-NA adoption pulls forward.

  $1,350.00 bear — China export curbs tighten and logic customers push out tool intake.

• AVGOBroadcomcompute

  hold2.37%73
  flow steadyconf

  Funder

  Custom-silicon ASIC leader (~60-70% share) plus VMware infrastructure-software lock-in: 68.6% GM, 47.3% OM, 35.2% FCF margin, 13x interest cover, $7B+ buyback. Wind: AI semiconductor revenue $16.7B (+221% YoY); Norges NEW $24.9B, Temasek/KIC adding in Q2. The reported NEAM (Berkshire subsidiary) exit is a small, non-core holder and does not offset the sovereign adds.

  Unwind

  AI custom-chip revenue stalling below a ~$25B run-rate; hyperscalers in-sourcing and displacing the ASIC franchise across multiple named accounts; VMware churn accelerating.

  Catalyst

  FQ4 print ~Dec 10; new XPU customer ramps.

  Scenarios · 12mo targets

  $430.00 base

  $500.00 bull — Two more hyperscaler XPU programs ramp and AI revenue guidance steps up again.

  $270.00 bear — A hyperscaler in-sources its ASIC and VMware renewals disappoint.

• ANETArista Networkscompute

  hold2.71%72
  flow acceleratingconf

  Funder

  Hyperscaler-networking franchise and share-gainer since 2004: 63.5% GM, 43.9% OM, 37.9% FCF margin, net cash, single-image EOS. Wind: AI-fabric customers up from 4-5 to 100+, $9.7B purchase commitments; Norges/KIC/Temasek holding; Citadel +61.6% in Q2.

  Unwind

  Microsoft+Meta >50% of revenue while revenue decelerates; Spectrum-X or whitebox displacing EOS in a NAMED hyperscaler footprint; GM breaking below 60%; purchase commitments unwinding.

  Catalyst

  Q3 print ~Nov 4: AI networking revenue target.

  Scenarios · 12mo targets

  $245.00 base

  $290.00 bull — Scale-up Ethernet wins and enterprise AI broaden the customer base, and the AI revenue target is raised.

  $150.00 bear — Spectrum-X takes a major cloud and the multiple compresses from its premium.

• AEISAdvanced Energy Industriescompute

  hold2.41%67
  flow steadyconf

  Funder

  Starter. 45-year incumbent in precision RF/DC plasma power, designed into etch and deposition recipes at the WFE OEMs; requalifying the supply means requalifying the recipe. Wind: Q2 rev +30% to $574M, guidance raised, AI data-center power plus a WFE recovery, Zacks Rank #1 on estimates up 23%.

  Unwind

  GM sustained below 36% on MKS/Comet/Delta price competition; semiconductor-segment revenue declining for two consecutive quarters; data-center power share loss to Vertiv or Delta.

  Catalyst

  Q3 print ~Nov 2: data-center power mix and GM.

  Scenarios · 12mo targets

  $330.00 base

  $390.00 bull — Data-center power wins scale and WFE recovers, pushing GM toward 40%.

  $210.00 bear — Price competition erodes GM and WFE spending pauses.

• BEAMBeam Therapeuticsbiology

  hold1.23%39
  flow steadyconf

  Funder

  Growth-starter sleeve, sized small by design. Base-editing origin platform (David Liu/Broad): single-base correction without double-strand breaks. ~$1.2B cash funds BEAM-302 (AATD) into 2028. Wind: ARK +10.23M, Fidelity +12.61M and T. Rowe +3.42M sh; FDA feedback supports an accelerated pathway for BEAM-302.

  Unwind

  A hepatotoxicity or off-target signal in BEAM-302; a discounted equity raise; cash runway breaking before AATD proof; FDA walking back the accelerated pathway.

  Catalyst

  BEAM-302 dose-escalation update; Q3 cash print ~Nov 3.

  Scenarios · 12mo targets

  $32.00 base

  $50.00 bull — BEAM-302 data shows durable functional AAT correction and the accelerated filing path firms up.

  $12.00 bear — A safety signal or efficacy plateau forces a discounted raise.

• BKNGBooking Holdingsgeneral

  hold2.50%73
  flow acceleratingconf

  Funder

  Dominant two-sided travel marketplace (39.5% OTA share vs Expedia 21.8%, 29M+ listings) on 33.1% OM and 26.9% FCF margin, 0.4x ND/EBITDA. Twenty years of returning essentially all FCF via buybacks; Genius loyalty drives ~50% of room nights direct. Wind: Norges +12.43M, Temasek +5228%, Citadel +85% and KIC in Q2. Opened 3 days ago; lock active.

  Unwind

  Take-rate falling >50bp YoY for two consecutive quarters (AI-agent or Google disintermediation showing up in the numbers, not the headlines); room-night growth <5% with direct mix stalling. The Meta Muse/Expedia agent tie-up is a watch item, not a break.

  Catalyst

  Q3 print ~Nov 3: take-rate, direct mix, room nights.

  Scenarios · 12mo targets

  $185.00 base

  $215.00 bull — Direct mix passes 55%, take-rate holds and buybacks shrink the share count ~5%/yr.

  $130.00 bear — AI booking agents commoditize demand capture and take-rate compresses.

Warnings

• §5.4 dry-powder: cash_pct 20.8% above base band top 20% allowed by §3b unfilled-sleeve headroom (+17.5pp, eff top 37.5%)
• cash_band: final cash 20.8% above neutral base band top 20% (escalator active: extension; §3b dry-powder headroom +17.5pp (unfilled opportunistic sleeve → cash)) (§5.4)

Lock refusals and overrides

The 30-day lock refused nothing and nothing overrode it this run.

Cost breakdown

Per-call cost computed from the published list price of the model that answered. Cache-read tokens billed at 10% of input. See Cost & ROI for the rolling 30-day ledger.